Literature DB >> 31038598

Diagnostic performance of thyroid ultrasound in Hürthle cell carcinomas.

Nathalie Oliveira Santana1, Ricardo Miguel Costa Freitas2, Vinicius Neves Marcos2, Maria Cristina Chammas3, Rosalinda Yossie Asato Camargo1, Cláudia Kliemann Schmerling4, Felipe Augusto Brasileiro Vanderlei5, Ana Oliveira Hoff6, Suemi Marui1, Debora Lucia Seguro Danilovic1,6.   

Abstract

OBJECTIVE: Hürthle cell carcinomas (HCCs) of the thyroid have been recently reclassified as a separate entity due to their distinct clinical and molecular profiles. Few studies have assessed the ability of preoperative characteristics in differentiating HCCs from Hürthle cell adenomas (HCAs) due to the low prevalence of both lesions. This study aimed to compare the preoperative features of HCCs and HCAs and evaluate the diagnostic performance of ultrasound in distinguishing between both. SUBJETCS AND METHODS: Retrospective study including 101 patients (52 HCCs and 49 HCAs) who underwent thyroid surgery from 2000 to 2016. Clinical, ultrasonographic, and histological data were reviewed. Diagnostic performance of suspicious sonographic features was analyzed in 51 cases (24 HCCs and 27 HCAs).
RESULTS: Hürthle cell neoplasms were predominant in females. Subjects ≥ 55 years represented 58% of the cases of HCCs and 53% of those of HCAs. Carcinomas were significantly larger (p < 0.001), and a tumor size ≥ 4 cm significantly increased the risk of malignancy (odds ratio 3.67). Other clinical, cytologic, and sonographic data were similar between HCCs and HCAs. Among the HCCs, the lesions were purely solid in 54.2%, hypoechoic in 37.5%, and had coarse calcifications in 12.5%, microcalcifications in 8.3%, irregular contours in 4.2%, and a taller-than-wide shape in 16.7%. Predominantly/exclusive intranodular vascularization was observed in 52.6%. Overall, 58% of the HCCs were classified as TI-RADS 4 or 5 compared with 48% of the HCAs. TI-RADS 4 or 5 had a specificity of only 51.8% and a positive likelihood ratio of 1.21.
CONCLUSIONS: Apart from the lesion size, no other preoperative feature adequately distinguished HCCs from HCAs. Sonographic characteristics raising suspicion for malignancy, which are mostly present in papillary carcinomas, were infrequent in HCCs. New tools must be developed to improve preoperative diagnosis and deferral of surgery in cases of adenomas.

Entities:  

Mesh:

Year:  2019        PMID: 31038598     DOI: 10.20945/2359-3997000000131

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  5 in total

1.  Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Jatin P Shah; Alvaro Sanabria; Abir Al Ghuzlan; Carl E Silver; Ashok R Shaha; Peter Angelos; Dana M Hartl; Antti A Mäkitie; Kerry D Olsen; Randall P Owen; Gregory W Randolph; Ricard Simó; Ralph P Tufano; Luiz P Kowalski; Mark E Zafereo; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2021-08-22       Impact factor: 3.845

2.  Hürthle cell neoplasms of the thyroid: Pathologic outcomes and ultrasonographic analysis.

Authors:  Timothy J Shin; Cyrus C Rabbani; Henna D Murthy; Katie Traylor; Michael W Sim
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-10-07

3.  Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea.

Authors:  Meihua Jin; Eun Sook Kim; Bo Hyun Kim; Hee Kyung Kim; Yea Eun Kang; Min Ji Jeon; Tae Yong Kim; Ho-Cheol Kang; Won Bae Kim; Young Kee Shong; Mijin Kim; Won Gu Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-10-28

4.  Ultrasonographic characteristics of Hürthle cell neoplasms: prediction of malignancy.

Authors:  Min Je Kim; Jung Hee Shin; Soo Yeon Hahn; Young Lyun Oh; Sun Wook Kim; Tae Hyuk Kim; Yaeji Lim; Sanghyuk Lee
Journal:  Ultrasonography       Date:  2022-04-14

Review 5.  Molecular Aspects of Thyroid Calcification.

Authors:  Luciana Bueno Ferreira; Etel Gimba; João Vinagre; Manuel Sobrinho-Simões; Paula Soares
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.